Has the rebound opportunity arrived? Hong Kong stocks welcome a strong start in May
Featured in The Lancet | BeiJieMai® Global Phase III MANEUVER Study Receives Recognition from Top Journal
On March 9, 2026, Shanghai Hebao Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as 'Hebao Pharma,' HKEX code: 02256.HK) announced that the results of its global multicenter Phase III MANEUVER study on BeiJieMai® (Pimicotinib Hydrochloride Capsules), a highly selective CSF-1R small molecule inhibitor independently developed by the company, were officially published in the internationally renowned medical journal The Lancet on March 5, Central European Time [1]. The publication of this paper marks a new milestone for Hebao Pharma's innovative therapy in terms of clinical research quality, data integrity, and international academic recognition.$ABBISKO-B (02256.HK)$
![On March 9, 2026, Shanghai Hebao Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as 'Hebao Pharma,' HKEX code: 02256.HK) announced that the results of its global multicenter Phase III MANEUVER study on BeiJieMai® (Pimicotinib Hydrochloride Capsules), a highly selective CSF-1R small molecule inhibitor independently developed by the company, were officially published in the internationally renowned medical journal The Lancet on March 5, Central European Time [1]. The publication of this paper marks a new milestone for Hebao Pharma's innovative therapy in terms of clinical research quality, data integrity, and international academic recognition.$ABBISKO-B (02256.HK)$ The MANEUVER study enrolled 94 participants across more than 30 clinical centers worldwide, with over half of the patients coming from outside China. Data shows that BeiJieMai® achieved significant efficacy and good safety in patients with tenosynovial giant cell tumor (TGCT) [2]. Global commercial rights for BeiJieMai® are held by Merck, and it received approval from the National Medical Products Administration (NMPA) of China in December 2025 for marketing to treat adult patients with symptomatic TGCT where surgical removal may cause functional limitations or lead to serious complications. Meanwhile, the New Drug Application (NDA) submitted by BeiJieMai® to the U.S. Food and Drug Administration (FDA) has been formally accepted, while its marketing applications in other markets are currently under review by relevant regulatory authorities.](https://nnqimage.futunn.com/sns_client_feed/40000814/20260309/fc553e38a91119d54282e932dfbaad84.jpg/big?area=1&is_public=true&imageMogr2/ignore-error/1/format/webp)
The MANEUVER study enrolled 94 participants across more than 30 clinical centers worldwide, with over half of the patients coming from outside China. Data shows that BeiJieMai® achieved significant efficacy and good safety in patients with tenosynovial giant cell tumor (TGCT) [2].
Global commercial rights for BeiJieMai® are held by Merck, and it received approval from the National Medical Products Administration (NMPA) of China in December 2025 for marketing to treat adult patients with symptomatic TGCT where surgical removal may cause functional limitations or lead to serious complications. Meanwhile, the New Drug Application (NDA) submitted by BeiJieMai® to the U.S. Food and Drug Administration (FDA) has been formally accepted, while its marketing applications in other markets are currently under review by relevant regulatory authorities.
References
1.Xu H, Niu X, Ravi V, et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. Lancet. Published online 2026.
2.Xiaohui Niu et al. Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study. J Clin Oncol 43, 11500-11500(2025).
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments
to post a comment
1